0001193125-24-022692.txt : 20240202 0001193125-24-022692.hdr.sgml : 20240202 20240202130625 ACCESSION NUMBER: 0001193125-24-022692 CONFORMED SUBMISSION TYPE: SC 13G/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20240202 DATE AS OF CHANGE: 20240202 GROUP MEMBERS: CT SPV INVESTMENT LP GROUP MEMBERS: IPG CAYMAN LP GROUP MEMBERS: IPG USA SCO LP SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: Carisma Therapeutics Inc. CENTRAL INDEX KEY: 0001485003 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 262025616 STATE OF INCORPORATION: PA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-87951 FILM NUMBER: 24589876 BUSINESS ADDRESS: STREET 1: 3675 MARKET STREET STREET 2: SUITE 200 CITY: PHILADELPHIA STATE: PA ZIP: 19104 BUSINESS PHONE: 2674916422 MAIL ADDRESS: STREET 1: 3675 MARKET STREET STREET 2: SUITE 200 CITY: PHILADELPHIA STATE: PA ZIP: 19104 FORMER COMPANY: FORMER CONFORMED NAME: Sesen Bio, Inc. DATE OF NAME CHANGE: 20180516 FORMER COMPANY: FORMER CONFORMED NAME: Eleven Biotherapeutics, Inc. DATE OF NAME CHANGE: 20100223 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: Longview Innovation Corp. CENTRAL INDEX KEY: 0001963826 ORGANIZATION NAME: IRS NUMBER: 990384304 STATE OF INCORPORATION: DE FILING VALUES: FORM TYPE: SC 13G/A BUSINESS ADDRESS: STREET 1: 1 RIGHTER PARKWAY, SUITE 260 CITY: WILMINGTON STATE: DE ZIP: 19803 BUSINESS PHONE: 302-752-1055 MAIL ADDRESS: STREET 1: 1 RIGHTER PARKWAY, SUITE 260 CITY: WILMINGTON STATE: DE ZIP: 19803 FORMER COMPANY: FORMER CONFORMED NAME: IP Group, Inc. DATE OF NAME CHANGE: 20230127 SC 13G/A 1 d682906dsc13ga.htm SC 13G/A SC 13G/A

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)*

 

 

Carisma Therapeutics Inc.

(Name of Issuer)

 

 

Common Stock, $0.001 par value per share

(Title of Class of Securities)

14216R 101

(CUSIP Number)

December 31, 2023

(Date of Event Which Requires Filing of this Statement)

 

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b)

☒ Rule 13d-1(c)

☐ Rule 13d-1(d)

 

*

The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

CUSIP No. 14216R 101    Page 2

 

 1   

 NAME OF REPORTING PERSON:

 

 Longview Innovation Corp.

 

 I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY):

 99-0384304

 2  

 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS):

 (a) ☐  (b) ☐

 

 3  

 SEC USE ONLY:

 

 4  

 CITIZENSHIP OR PLACE OF ORGANIZATION:

 

 Delaware

NUMBER OF

SHARES

 BENEFICIALLY 

OWNED BY

EACH

REPORTING

PERSON

WITH

    5   

 SOLE VOTING POWER

 

 0

   6  

 SHARED VOTING POWER

 

 2,713,232

   7  

 SOLE DISPOSITIVE POWER

 

 0

   8  

 SHARED DISPOSITIVE POWER

 

 2,713,232

 9   

 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON:

 

 2,713,232

10  

 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS):

 

 ☐

11  

 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9):

 

 6.7%(1)

12  

 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS):

 

 CO

 

(1)

Based on 40,356,806 shares of the Issuer’s common stock outstanding as of November 6, 2023 as reported in the Issuer’s Form 10-Q for the quarterly period ended September 30, 2023, filed with the Securities and Exchange Commission on November 9, 2023.

CUSIP No. 14216R 101    Page 3

 

 1   

 NAME OF REPORTING PERSON:

 

 IPG Cayman LP

 

 I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY):

 98-1533434

 2  

 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS):

 (a) ☐  (b) ☐

 

 3  

 SEC USE ONLY:

 

 4  

 CITIZENSHIP OR PLACE OF ORGANIZATION:

 

 Cayman Islands

NUMBER OF

SHARES

 BENEFICIALLY 

OWNED BY

EACH

REPORTING

PERSON

WITH

    5   

 SOLE VOTING POWER

 

 0

   6  

 SHARED VOTING POWER

 

 2,067,924

   7  

 SOLE DISPOSITIVE POWER

 

 0

   8  

 SHARED DISPOSITIVE POWER

 

 2,067,924

 9   

 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON:

 

 2,067,924

10  

 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS):

 

 ☐

11  

 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9):

 

 5.1%(1)

12  

 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS):

 

 PN

 

(1)

Based on 40,356,806 shares of the Issuer’s common stock outstanding as of November 6, 2023 as reported in the Issuer’s Form 10-Q for the quarterly period ended September 30, 2023, filed with the Securities and Exchange Commission on November 9, 2023.

CUSIP No. 14216R 101    Page 4

 

 1   

 NAME OF REPORTING PERSON:

 

 CT SPV Investment LP

 

 I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY):

 86-2213372

 2  

 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS):

 (a) ☐  (b) ☐

 

 3  

 SEC USE ONLY:

 

 4  

 CITIZENSHIP OR PLACE OF ORGANIZATION:

 

 Delaware

NUMBER OF

SHARES

 BENEFICIALLY 

OWNED BY

EACH

REPORTING

PERSON

WITH

    5   

 SOLE VOTING POWER

 

 0

   6  

 SHARED VOTING POWER

 

 377,444

   7  

 SOLE DISPOSITIVE POWER

 

 0

   8  

 SHARED DISPOSITIVE POWER

 

 377,444

 9   

 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON:

 

 377,444

10  

 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS):

 

 ☐

11  

 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9):

 

 0.9%(1)

12  

 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS):

 

 PN

 

(1)

Based on 40,356,806 shares of the Issuer’s common stock outstanding as of November 6, 2023 as reported in the Issuer’s Form 10-Q for the quarterly period ended September 30, 2023, filed with the Securities and Exchange Commission on November 9, 2023.

CUSIP No. 14216R 101    Page 5

 

 1   

 NAME OF REPORTING PERSON:

 

 IPG USA SCO LP

 

 I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY):

 None

 2  

 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS):

 (a) ☐  (b) ☐

 

 3  

 SEC USE ONLY:

 

 4  

 CITIZENSHIP OR PLACE OF ORGANIZATION:

 

 Scotland

NUMBER OF

SHARES

 BENEFICIALLY 

OWNED BY

EACH

REPORTING

PERSON

WITH

    5   

 SOLE VOTING POWER

 

 0

   6  

 SHARED VOTING POWER

 

 267,864

   7  

 SOLE DISPOSITIVE POWER

 

 0

   8  

 SHARED DISPOSITIVE POWER

 

 267,864

 9   

 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON:

 

 267,864

10  

 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS):

 

 ☐

11  

 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9):

 

 0.7%(1)

12  

 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS):

 

 PN

 

(1)

Based on 40,356,806 shares of the Issuer’s common stock outstanding as of November 6, 2023 as reported in the Issuer’s Form 10-Q for the quarterly period ended September 30, 2023, filed with the Securities and Exchange Commission on November 9, 2023.

Item 1

(a) Name of Issuer:

Carisma Therapeutics Inc.

(b) Address of Issuer’s Principal Executive Offices:

3675 Market Street, Suite 200

Philadelphia, Pennsylvania 19104

Item 2

(a) Names of Persons Filing:

Each of the following is a reporting person (“Reporting Person”):

Longview Innovation Corp.

IPG Cayman LP

CT SPV Investment LP

IPG USA SCO LP

(b) Address or principal business office or, if none, residence:

The address for the principal business office of the Reporting Persons is:

c/o Longview Innovation Corp.

3411 Silverside Road

Baynard Building, Suite 252

Wilmington, Delaware 19810

(c) Citizenship:

Reference is made to the response to item 4 on each of pages 2-5 of this Schedule 13G (this “Schedule”), which  responses are incorporated herein by reference.

(d) Title and Class of Securities:

Common Stock, par value $0.001 per share.

(e) CUSIP No.:

14216R 101

Item 3. If this statement is filed pursuant to Rules 13d-1(b) or 13d-2(b) or (c), check whether the person filing is a:

Not applicable.

Item 4. Ownership

Reference is hereby made to the responses to items 5-9 and 11 on each of pages 2-5 of this Schedule, which responses are incorporated herein by reference.

Item 5. Ownership of Five Percent or Less of a Class

Not applicable.

Item 6. Ownership of More than 5 Percent on Behalf of Another Person

Not applicable.

Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not applicable.

Item 8. Identification and Classification of Members of the Group

Not applicable.

Item 9. Notice of Dissolution of Group

Not applicable.

Item 10. Certifications

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

SIGNATURES

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: February 2, 2024

 

LONGVIEW INNOVATION CORP.
By:  

/s/ Brandon Fleishman

Name:   Brandon Fleishman
Title:   General Counsel
IPG CAYMAN LP
By: IPG USA (GP) LLC, its General Partner
By: Longview Innovation Corp., its Fund Manager
By:  

/s/ Brandon Fleishman

Name:   Brandon Fleishman
Title:   Authorized Signatory
IPG USA SCO LP
By: Longview Innovation Corp., its delegated manager
By:  

/s/ Brandon Fleishman

Name:   Brandon Fleishman
Title:   Authorized Signatory
CT SPV INVESTMENT LP
By: Longview Innovation Corp., its general partner
By:  

/s/ Brandon Fleishman

Name:   Brandon Fleishman
Title:   Authorized Signatory